Company intelligence
Ori Biotech
We're on a mission to enable widespread patient access to a new generation of lifesaving Cell and Gene Therapies.
About Ori Biotech
Ori Biotech is a London- and Philadelphia-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalized, lifesaving treatments. By fully automating and standardizing CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.
Verified activity
Signals from Ori Biotech
4 published signals
Presence & Recognition
Ori Biotech highlighted that First Alert 6 shared the story of Lauren Koop Daughtrey, who received the first CAR-T cell therapy for lupus at the Fred and Pamela Buffett Cancer Center at Nebraska Medicine after two years on.
Reported by Ori Biotech
Research & Knowledge
Ori Biotech published new research in Nature Cancer showing that iron can limit the survival of CAR-T cells after infusion, and blocking the process improves their staying power.
Reported by Ori Biotech
Research & Knowledge
Ori Biotech customer Kincell Bio tested IRO across its cell therapy workflows and saw gains in biological performance alongside automation for T-cell manufacturing.
Reported by Ori Biotech